<p>Compass Therapeutics（納斯達克代碼：CMPX - 獲取免費報告）於週四發佈了季度財報。該公司報告季度每股收益為（$0.09），超出市場共識預期的（$0.10）$0.01，FiscalAI 報道。</p>
<p>獲取 <strong>Compass Therapeutics</strong> 的提醒：</p>
<h2>Compass Therapeutics 股票上漲 2.5%</h2>
<ul>
<li>分析師仍看好的前三家高動量公司</li>
</ul>
<p>週四，CMPX 股票上漲 $0.14，達到 $5.83。該公司的交易量為 453,195 股，而其平均交易量為 2,287,071 股。該公司的市值為 10.4 億美元，市盈率為-12.96，貝塔值為 1.48。Compass Therapeutics 的一年最低價為 $1.33，一年最高價為 $6.88。該公司的 50 日移動平均價格為 $5.88，200 日移動平均價格為 $4.77。</p>
<h2>Compass Therapeutics 的機構交易</h2>
<p>一些機構投資者最近調整了對該公司的持股。拉塞爾投資集團在第三季度將其在 Compass Therapeutics 的持股比例提高了 3,933.7%。拉塞爾投資集團目前擁有 7,785 股該公司的股票，價值 27,000 美元，此前在上個季度購買了 7,592 股。Xponance LLC 在第四季度購買了 Compass Therapeutics 的新股份，價值 55,000 美元。CIBC Bancorp USA Inc.在第三季度獲得了 Compass Therapeutics 的新職位，價值 37,000 美元。Creative Planning 在第二季度購買了 Compass Therapeutics 的新職位，價值 30,000 美元。最後，勝利資本管理公司在第三季度將其在 Compass Therapeutics 的持股比例提高了 20.6%。勝利資本管理公司目前擁有 12,652 股該公司的股票，價值 44,000 美元，此前在上個季度購買了 2,164 股。目前 68.43% 的股票由機構投資者持有。</p>
<h2>華爾街分析師的看法</h2>
<p>一些研究分析師最近對該公司發表了看法。Weiss Ratings 在 1 月 21 日的研究報告中重新發布了對 Compass Therapeutics 股票的 “賣出（d-）” 評級。威廉·布萊爾在 1 月 5 日的報告中開始覆蓋 Compass Therapeutics，並對該公司給予了 “跑贏大盤” 的評級。Canaccord Genuity Group 在 2 月 4 日的研究報告中對 Compass Therapeutics 設定了$13.00 的目標價格。Craig Hallum 在 2 月 13 日的研究報告中開始覆蓋 Compass Therapeutics，並設定了 “買入” 評級和$15.00 的目標價格。最後，雷蒙德·詹姆斯金融公司在 1 月 6 日的研究報告中重申了 “跑贏大盤” 的評級，並對 Compass Therapeutics 的股票設定了$9.00 的目標價格。一位投資分析師對該股票給予了強烈買入評級，十二位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Compass Therapeutics 目前的共識評級為 “適度買入”，共識目標價格為$13.36。</p>
<p><strong>獲取我們關於 Compass Therapeutics 的最新股票報告</strong></p>
<h2>Compass Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Compass Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於新型免疫腫瘤療法的發現和開發。公司總部位於馬薩諸塞州劍橋，專注於工程化單克隆抗體候選藥物，旨在增強 T 細胞介導的抗腫瘤反應。Compass 利用專有抗體平台識別和優化調節免疫檢查點通路和腫瘤微環境的生物製劑。</p>
<p>該公司的主要項目包括 CTX-471，一種雙特異性抗體，靶向 PD-1 和 PD-L1 檢查點，以及 DSP107，一種 CD47-SIRPα通路調節劑，旨在破壞癌細胞上的 “別吃我” 信號。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Compass Therapeutics</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國 1776 年再次發生</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 你的銀行賬户</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 Compass Therapeutics 嗎？</h2>
<p>在你考慮 Compass Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Compass Therapeutics 並不在名單上。</p>
<p>雖然 Compass Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

CMPX

<p>Compass Therapeutics（納斯達克代碼：CMPX）報告本季度每股收益為（$0.09），超出預期的（$0.10）$0.01。公告發布後，股價上漲 2.5%，至$5.83。該公司的市值為 10.4 億美元，市盈率為-12.96。機構投資者持有 68.43% 的股份。分析師的評級意見不一，普遍共識為 “適度買入”，目標價為$13.36。Compass 專注於開發免疫腫瘤療法，包括針對 PD-1 和 PD-L1 檢查點的雙特異性抗體</p>

<p>Compass Therapeutics (NASDAQ:CMPX - Get Free Report) released its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01, FiscalAI reports.</p>
<div class="lb-trans"><p>Compass Therapeutics（納斯達克代碼：CMPX - 獲取免費報告）於週四發佈了季度財報。該公司報告季度每股收益為（$0.09），超出市場共識預期的（$0.10）$0.01，FiscalAI 報道。</p>
</div><p>Get <strong>Compass Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Compass Therapeutics</strong> 的提醒：</p>
</div><h2>Compass Therapeutics Stock Up 2.5%</h2>
<div class="lb-trans"><h2>Compass Therapeutics 股票上漲 2.5%</h2>
</div><ul>
<li>Top 3 High-Momentum Companies Analysts Are Still Bullish On</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師仍看好的前三家高動量公司</li>
</ul>
</div><p>CMPX traded up $0.14 during trading on Thursday, hitting $5.83. The company had a trading volume of 453,195 shares, compared to its average volume of 2,287,071. The company has a market capitalization of $1.04 billion, a PE ratio of -12.96 and a beta of 1.48. Compass Therapeutics has a one year low of $1.33 and a one year high of $6.88. The firm's 50-day moving average price is $5.88 and its 200 day moving average price is $4.77.</p>
<div class="lb-trans"><p>週四，CMPX 股票上漲 $0.14，達到 $5.83。該公司的交易量為 453,195 股，而其平均交易量為 2,287,071 股。該公司的市值為 10.4 億美元，市盈率為-12.96，貝塔值為 1.48。Compass Therapeutics 的一年最低價為 $1.33，一年最高價為 $6.88。該公司的 50 日移動平均價格為 $5.88，200 日移動平均價格為 $4.77。</p>
</div><h2>Institutional Trading of Compass Therapeutics</h2>
<div class="lb-trans"><h2>Compass Therapeutics 的機構交易</h2>
</div><p>A number of institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. raised its position in Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company's stock valued at $27,000 after buying an additional 7,592 shares during the last quarter. Xponance LLC bought a new stake in shares of Compass Therapeutics in the fourth quarter worth $55,000. CIBC Bancorp USA Inc. acquired a new position in Compass Therapeutics during the third quarter worth $37,000. Creative Planning bought a new position in Compass Therapeutics in the second quarter valued at $30,000. Finally, Victory Capital Management Inc. increased its stake in Compass Therapeutics by 20.6% in the 3rd quarter. Victory Capital Management Inc. now owns 12,652 shares of the company's stock valued at $44,000 after buying an additional 2,164 shares during the last quarter. 68.43% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>一些機構投資者最近調整了對該公司的持股。拉塞爾投資集團在第三季度將其在 Compass Therapeutics 的持股比例提高了 3,933.7%。拉塞爾投資集團目前擁有 7,785 股該公司的股票，價值 27,000 美元，此前在上個季度購買了 7,592 股。Xponance LLC 在第四季度購買了 Compass Therapeutics 的新股份，價值 55,000 美元。CIBC Bancorp USA Inc.在第三季度獲得了 Compass Therapeutics 的新職位，價值 37,000 美元。Creative Planning 在第二季度購買了 Compass Therapeutics 的新職位，價值 30,000 美元。最後，勝利資本管理公司在第三季度將其在 Compass Therapeutics 的持股比例提高了 20.6%。勝利資本管理公司目前擁有 12,652 股該公司的股票，價值 44,000 美元，此前在上個季度購買了 2,164 股。目前 68.43% 的股票由機構投資者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師的看法</h2>
</div><p>A number of research analysts have recently weighed in on the company. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Compass Therapeutics in a research note on Wednesday, January 21st. William Blair started coverage on Compass Therapeutics in a report on Monday, January 5th. They issued an &#34;outperform&#34; rating for the company. Canaccord Genuity Group set a $13.00 target price on Compass Therapeutics in a research note on Wednesday, February 4th. Craig Hallum started coverage on Compass Therapeutics in a research report on Friday, February 13th. They set a &#34;buy&#34; rating and a $15.00 target price for the company. Finally, Raymond James Financial reiterated an &#34;outperform&#34; rating and issued a $9.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, Compass Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $13.36.</p>
<div class="lb-trans"><p>一些研究分析師最近對該公司發表了看法。Weiss Ratings 在 1 月 21 日的研究報告中重新發布了對 Compass Therapeutics 股票的 “賣出（d-）” 評級。威廉·布萊爾在 1 月 5 日的報告中開始覆蓋 Compass Therapeutics，並對該公司給予了 “跑贏大盤” 的評級。Canaccord Genuity Group 在 2 月 4 日的研究報告中對 Compass Therapeutics 設定了$13.00 的目標價格。Craig Hallum 在 2 月 13 日的研究報告中開始覆蓋 Compass Therapeutics，並設定了 “買入” 評級和$15.00 的目標價格。最後，雷蒙德·詹姆斯金融公司在 1 月 6 日的研究報告中重申了 “跑贏大盤” 的評級，並對 Compass Therapeutics 的股票設定了$9.00 的目標價格。一位投資分析師對該股票給予了強烈買入評級，十二位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat 的數據，Compass Therapeutics 目前的共識評級為 “適度買入”，共識目標價格為$13.36。</p>
</div><p><strong>Get Our Latest Stock Report on Compass Therapeutics</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Compass Therapeutics 的最新股票報告</strong></p>
</div><h2>Compass Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Compass Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.</p>
<div class="lb-trans"><p>Compass Therapeutics, Inc 是一家臨牀階段的生物技術公司，致力於新型免疫腫瘤療法的發現和開發。公司總部位於馬薩諸塞州劍橋，專注於工程化單克隆抗體候選藥物，旨在增強 T 細胞介導的抗腫瘤反應。Compass 利用專有抗體平台識別和優化調節免疫檢查點通路和腫瘤微環境的生物製劑。</p>
</div><p>The company's lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don't eat me” signals on cancer cells.</p>
<div class="lb-trans"><p>該公司的主要項目包括 CTX-471，一種雙特異性抗體，靶向 PD-1 和 PD-L1 檢查點，以及 DSP107，一種 CD47-SIRPα通路調節劑，旨在破壞癌細胞上的 “別吃我” 信號。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精選故事</h2>
</div><ul>
<li>Five stocks we like better than Compass Therapeutics</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>America’s 1776 happening again</li>
<li>Buy this Gold Stock Before May 2026</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
<li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Compass Therapeutics</li>
<li>華爾街害怕的黃金圖表……</li>
<li>美國 1776 年再次發生</li>
<li>在 2026 年 5 月之前購買這隻黃金股票</li>
<li>一位前 CIA 特工對即將到來的崩潰的看法</li>
<li>用這四個簡單步驟 “防止美聯儲影響” 你的銀行賬户</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q01QWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=CMPX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Compass Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 Compass Therapeutics 嗎？</h2>
</div><p>Before you consider Compass Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Compass Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已經識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Compass Therapeutics 並不在名單上。</p>
</div><p>While Compass Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Compass Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Compass Therapeutics（納斯達克股票代碼：CMPX）發佈財報，每股收益比預期高出 0.01 美元